Which has preferable earnings and valuation, NVCR or NPCE?

NeuroPace has lower revenue, but higher earnings than NovoCure. NeuroPace is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 2.97 -$136.23M -$1.30 N/A NeuroPace $99.99M 4.90 -$21.47M -$0.57 N/A

Is NVCR or NPCE more profitable?

NeuroPace has a net margin of -19.34% compared to NovoCure's net margin of -21.25%. NovoCure's return on equity of -44.00% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -21.25% -44.00% -15.85% NeuroPace -19.34% -105.64% -16.51%

Does the media refer more to NVCR or NPCE?

In the previous week, NovoCure had 1 more articles in the media than NeuroPace. MarketBeat recorded 4 mentions for NovoCure and 3 mentions for NeuroPace. NeuroPace's average media sentiment score of 0.47 beat NovoCure's score of 0.20 indicating that NeuroPace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral NeuroPace 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LMAT or NPCE?

In the previous week, NeuroPace had 2 more articles in the media than LeMaitre Vascular. MarketBeat recorded 3 mentions for NeuroPace and 1 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.63 beat NeuroPace's score of 0.47 indicating that LeMaitre Vascular is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive NeuroPace 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, ATEC or NPCE?

NeuroPace has lower revenue, but higher earnings than Alphatec. NeuroPace is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alphatec $764.16M 2.06 -$143.36M -$0.71 N/A NeuroPace $99.99M 4.90 -$21.47M -$0.57 N/A

Is ATEC or NPCE more profitable?

Alphatec has a net margin of -13.49% compared to NeuroPace's net margin of -19.34%. NeuroPace's return on equity of -105.64% beat Alphatec's return on equity. Company Net Margins Return on Equity Return on Assets Alphatec -13.49% -6,752.24% -13.88% NeuroPace -19.34% -105.64% -16.51%

Does the media favor ATEC or NPCE?

In the previous week, Alphatec had 2 more articles in the media than NeuroPace. MarketBeat recorded 5 mentions for Alphatec and 3 mentions for NeuroPace. Alphatec's average media sentiment score of 0.75 beat NeuroPace's score of 0.47 indicating that Alphatec is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alphatec 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroPace 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, NPCE or OMCL?

Omnicell has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroPace $99.99M 4.90 -$21.47M -$0.57 N/A Omnicell $1.18B 1.24 $2.05M $0.84 38.37

Is NPCE or OMCL more profitable?

Omnicell has a net margin of 3.13% compared to NeuroPace's net margin of -19.34%. Omnicell's return on equity of 5.66% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets NeuroPace -19.34% -105.64% -16.51% Omnicell 3.13% 5.66% 3.57%

Does the media favor NPCE or OMCL?

In the previous week, NeuroPace and NeuroPace both had 3 articles in the media. Omnicell's average media sentiment score of 0.83 beat NeuroPace's score of 0.47 indicating that Omnicell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Omnicell 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KMTS or NPCE?

In the previous week, Kestra Medical Technologies had 16 more articles in the media than NeuroPace. MarketBeat recorded 19 mentions for Kestra Medical Technologies and 3 mentions for NeuroPace. NeuroPace's average media sentiment score of 0.47 beat Kestra Medical Technologies' score of -0.01 indicating that NeuroPace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kestra Medical Technologies 2 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral NeuroPace 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

NeuroPace (NPCE) Competitors

$14.28 +0.13 (+0.92%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$14.27 -0.01 (-0.07%)

As of 09/18/2026 06:37 PM Eastern

Compare

NPCE vs. NVCR, LMAT, ATEC, OMCL, and KMTS

Should you buy NeuroPace stock or one of its competitors? NeuroPace's main competitors and comparable companies include NovoCure (NVCR), LeMaitre Vascular (LMAT), Alphatec (ATEC), Omnicell (OMCL), and Kestra Medical Technologies (KMTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does NeuroPace compare to NovoCure?

NovoCure (NASDAQ:NVCR) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, NovoCure had 1 more articles in the media than NeuroPace. MarketBeat recorded 4 mentions for NovoCure and 3 mentions for NeuroPace. NeuroPace's average media sentiment score of 0.47 beat NovoCure's score of 0.20 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
NeuroPace	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeuroPace has lower revenue, but higher earnings than NovoCure. NeuroPace is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.97	-$136.23M	-$1.30	N/A
NeuroPace	$99.99M	4.90	-$21.47M	-$0.57	N/A

NeuroPace has a net margin of -19.34% compared to NovoCure's net margin of -21.25%. NovoCure's return on equity of -44.00% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
NeuroPace	-19.34%	-105.64%	-16.51%

NovoCure has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market. Comparatively, NeuroPace has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market.

84.6% of NovoCure shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 6.6% of NovoCure shares are held by company insiders. Comparatively, 19.2% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

NovoCure presently has a consensus price target of $21.20, indicating a potential upside of 27.02%. NeuroPace has a consensus price target of $19.33, indicating a potential upside of 35.39%. Given NeuroPace's stronger consensus rating and higher possible upside, analysts plainly believe NeuroPace is more favorable than NovoCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Summary

NeuroPace beats NovoCure on 11 of the 17 factors compared between the two stocks.

How does NeuroPace compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

In the previous week, NeuroPace had 2 more articles in the media than LeMaitre Vascular. MarketBeat recorded 3 mentions for NeuroPace and 1 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.63 beat NeuroPace's score of 0.47 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
NeuroPace	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

LeMaitre Vascular has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.94, indicating that its share price is 94% more volatile than the broader market.

LeMaitre Vascular has a net margin of 25.02% compared to NeuroPace's net margin of -19.34%. LeMaitre Vascular's return on equity of 15.63% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	25.02%	15.63%	10.06%
NeuroPace	-19.34%	-105.64%	-16.51%

LeMaitre Vascular currently has a consensus target price of $110.60, indicating a potential upside of 40.23%. NeuroPace has a consensus target price of $19.33, indicating a potential upside of 35.39%. Given LeMaitre Vascular's higher possible upside, analysts plainly believe LeMaitre Vascular is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

LeMaitre Vascular has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	7.23	$57.73M	$2.85	27.67
NeuroPace	$99.99M	4.90	-$21.47M	-$0.57	N/A

84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by insiders. Comparatively, 19.2% of NeuroPace shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

LeMaitre Vascular beats NeuroPace on 11 of the 17 factors compared between the two stocks.

How does NeuroPace compare to Alphatec?

Alphatec (NASDAQ:ATEC) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Alphatec has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.94, meaning that its stock price is 94% more volatile than the broader market.

In the previous week, Alphatec had 2 more articles in the media than NeuroPace. MarketBeat recorded 5 mentions for Alphatec and 3 mentions for NeuroPace. Alphatec's average media sentiment score of 0.75 beat NeuroPace's score of 0.47 indicating that Alphatec is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alphatec	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroPace	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeuroPace has lower revenue, but higher earnings than Alphatec. NeuroPace is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alphatec	$764.16M	2.06	-$143.36M	-$0.71	N/A
NeuroPace	$99.99M	4.90	-$21.47M	-$0.57	N/A

Alphatec currently has a consensus price target of $17.40, indicating a potential upside of 70.92%. NeuroPace has a consensus price target of $19.33, indicating a potential upside of 35.39%. Given Alphatec's higher probable upside, research analysts plainly believe Alphatec is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alphatec	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Alphatec has a net margin of -13.49% compared to NeuroPace's net margin of -19.34%. NeuroPace's return on equity of -105.64% beat Alphatec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alphatec	-13.49%	-6,752.24%	-13.88%
NeuroPace	-19.34%	-105.64%	-16.51%

66.4% of Alphatec shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 13.5% of Alphatec shares are held by company insiders. Comparatively, 19.2% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

NeuroPace beats Alphatec on 9 of the 17 factors compared between the two stocks.

How does NeuroPace compare to Omnicell?

NeuroPace (NASDAQ:NPCE) and Omnicell (NASDAQ:OMCL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

NeuroPace has a beta of 1.94, meaning that its share price is 94% more volatile than the broader market. Comparatively, Omnicell has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Omnicell has a net margin of 3.13% compared to NeuroPace's net margin of -19.34%. Omnicell's return on equity of 5.66% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-19.34%	-105.64%	-16.51%
Omnicell	3.13%	5.66%	3.57%

NeuroPace currently has a consensus target price of $19.33, suggesting a potential upside of 35.39%. Omnicell has a consensus target price of $57.86, suggesting a potential upside of 79.51%. Given Omnicell's higher probable upside, analysts plainly believe Omnicell is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

78.8% of NeuroPace shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 19.2% of NeuroPace shares are held by insiders. Comparatively, 2.9% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, NeuroPace and NeuroPace both had 3 articles in the media. Omnicell's average media sentiment score of 0.83 beat NeuroPace's score of 0.47 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omnicell	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omnicell has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	4.90	-$21.47M	-$0.57	N/A
Omnicell	$1.18B	1.24	$2.05M	$0.84	38.37

Summary

Omnicell beats NeuroPace on 11 of the 16 factors compared between the two stocks.

How does NeuroPace compare to Kestra Medical Technologies?

Kestra Medical Technologies (NASDAQ:KMTS) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

NeuroPace has higher revenue and earnings than Kestra Medical Technologies. NeuroPace is trading at a lower price-to-earnings ratio than Kestra Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kestra Medical Technologies	$95.13M	15.30	-$131.61M	-$2.67	N/A
NeuroPace	$99.99M	4.90	-$21.47M	-$0.57	N/A

Kestra Medical Technologies has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.94, meaning that its share price is 94% more volatile than the broader market.

In the previous week, Kestra Medical Technologies had 16 more articles in the media than NeuroPace. MarketBeat recorded 19 mentions for Kestra Medical Technologies and 3 mentions for NeuroPace. NeuroPace's average media sentiment score of 0.47 beat Kestra Medical Technologies' score of -0.01 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kestra Medical Technologies	2 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroPace	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kestra Medical Technologies currently has a consensus price target of $28.38, indicating a potential upside of 16.15%. NeuroPace has a consensus price target of $19.33, indicating a potential upside of 35.39%. Given NeuroPace's stronger consensus rating and higher possible upside, analysts clearly believe NeuroPace is more favorable than Kestra Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kestra Medical Technologies	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

NeuroPace has a net margin of -19.34% compared to Kestra Medical Technologies' net margin of -140.43%. Kestra Medical Technologies' return on equity of -63.83% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kestra Medical Technologies	-140.43%	-63.83%	-44.76%
NeuroPace	-19.34%	-105.64%	-16.51%

78.8% of NeuroPace shares are owned by institutional investors. 5.3% of Kestra Medical Technologies shares are owned by company insiders. Comparatively, 19.2% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

NeuroPace beats Kestra Medical Technologies on 13 of the 17 factors compared between the two stocks.

Get NeuroPace News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NPCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NPCE vs. The Competition

Export

Metric	NeuroPace	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$490.15M	$5.55B	$7.24B	$13.19B
Dividend Yield	N/A	1.80%	2.57%	12.81%
P/E Ratio	-25.05	25.34	274.93	25.38
Price / Sales	4.90	72.49	646.01	89.45
Price / Cash	N/A	32.64	76.25	51.42
Price / Book	25.05	5.69	10.46	6.33
Net Income	-$21.47M	$151.55M	$3.49B	$358.33M
7 Day Performance	1.71%	0.66%	0.59%	1.12%
1 Month Performance	1.85%	-3.33%	-1.74%	-2.39%
1 Year Performance	43.66%	6.79%	18.13%	5.35%

NeuroPace Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NPCE NeuroPace	3.1952 of 5 stars	$14.28 +0.9%	$19.33 +35.4%	+43.7%	$490.15M	$99.99M	N/A	220	News Coverage Positive News Analyst Forecast High Trading Volume
NVCR NovoCure	2.3325 of 5 stars	$16.36 +0.9%	$21.20 +29.6%	+31.5%	$1.91B	$655.35M	N/A	1,605	News Coverage
LMAT LeMaitre Vascular	4.9015 of 5 stars	$80.02 -0.9%	$110.60 +38.2%	-14.5%	$1.83B	$262.43M	28.10	655	Positive News
ATEC Alphatec	3.9954 of 5 stars	$10.72 -1.3%	$17.40 +62.3%	-34.5%	$1.66B	$815.05M	N/A	913	Positive News
OMCL Omnicell	4.1945 of 5 stars	$32.71 -2.4%	$57.86 +76.9%	+2.8%	$1.49B	$1.25B	38.90	3,580

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NPCE) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroPace (NPCE) Competitors